Form 8-K

8-K — SANUWAVE Health, Inc.

Accession: 0001628280-26-054459

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001417663

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — snwv-20260806.htm (Primary)

EX-99.1 (ex-991snwvpressreleasex806.htm)

GRAPHIC (logoa.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: snwv-20260806.htm · Sequence: 1

snwv-20260806

FALSE000141766300014176632026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 6, 2026

SANUWAVE Health, Inc.

(Exact name of registrant as specified in its charter)

Nevada 000-42552 20-1176000

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

9600 W. 76th Street, Suite 118, Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (952) 656-1029

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s)

Name of each exchange on which

registered

Common stock, par value $0.001 per share SNWV The Nasdaq Stock Market LLC

Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, Sanuwave Health, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2026. As previously announced, a business update via conference call will occur on August 7, 2026 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors.

The information in this Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit

No.

Description

99.1

Press Release dated August 6, 2026

104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SANUWAVE HEALTH, INC.

Dated: August 6, 2026

By: /s/ Peter Sorensen

Name: Peter Sorensen

Title: Chief Financial Officer

EX-99.1

Filename: ex-991snwvpressreleasex806.htm · Sequence: 2

Document

Exhibit 99.1

Sanuwave Announces Q2 FY2026 Financial Results

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025.

Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.

GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025.

EDEN PRAIRIE, MN, August 6, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-cleared wound care products, is pleased to provide its financial results for the three months ended June 30, 2026.

Quarter ended June 30, 2026

•Revenue for the three months ended June 30, 2026, totaled $9.7 million, an decrease of 3%, as compared to $10.1 million for the same period of 2025. Revenue for the three months ended June 30, 2026 was slightly above the high end of the revised guidance provided on June 16, 2026.

•82 Ultramist® systems were sold in Q2 2026 down from 116 in Q2 2025, and from 97 in Q1 2026.

•Ultramist® applicator revenue increased by 13% to $7.3 million in Q2 2026, versus $6.4 million for the same quarter last year.

•Gross margin as a percentage of revenue amounted to 76.2% for the three months ended June 30, 2026, versus 78.1% for the same period last year.

•For the three months ended June 30, 2026, operating (loss) income totaled $(0.3) million, compared to $1.4 million in Q2 2025.

•Net loss for the second quarter of 2026 was $0.7 million. This compares to net income of $0.6 million in the second quarter of 2025.

•Adjusted EBITDA [1] for the three months ended June 30, 2026, was $1.2 million versus Adjusted EBITDA of $3.2 million for the same period last year.

“2026 has been a challenging period for the advanced wound care market,” said Morgan Frank, CEO. “Despite this, Q2 was another all time record for Ultramist applicator unit volumes, which increased 13% sequentially from Q1 and 27% year on year. We take this to be a strong sign of ongoing demand for and confidence in the Ultramist system as a treatment modality for complex and non-healing wounds. As previously discussed, system sales were negatively impacted in the quarter both by ongoing stress in our customer base from CMS reimbursement changes and recoupments around allografts and by the emergence of a significant market for used Ultramist systems, which led to lower than expected sales by the Company. As a result, applicator sales accounted for approximately 75% of revenues in the quarter, a number above our target range of 60-65%. The silver lining on that seems to be that demand for systems during the quarter remained fairly robust if one includes our estimation of used sales on top of those sold by the Company. Moving on to the CMS proposed

rule for 2027 97610 reimbursement announced this July, obviously, this is neither what we were hoping for nor what we expected, especially in light of having just had a 14% increase in our proposed reimbursement rate in the HOPD setting come out a couple of weeks prior. While Sanuwave wholeheartedly supports CMS’s goal of accurate, data driven payment, we have some material disagreements with the methodology, process, and assumptions utilized by CMS in their proposed rule for 2027 and, as one might expect, will be active in the comment period to seek reconsideration before a final rule is issued. Our goal in this comment period will be to ensure that the data that drives this decision is both accurate and complete and that it reflects the full practitioner costs (and the systemic benefits) of providing treatment under 97610, which is, of course, the intent of these rules. We believe that we have a strong case to make and, with the support of a great many customers and academic institutions and thought leaders who have reached out with gracious offers to help, we plan to make it vigorously.”

Certain percentages presented in this earnings release are calculated from the underlying whole-dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes.

Financial Outlook

Owing to market conditions including the Medicare reimbursement developments discussed above, Sanuwave is withdrawing its previously issued fiscal year 2026 guidance which should no longer be relied upon. The Company will not provide quarterly or annual guidance until there is greater clarity on these topics and expects to reassess after CMS publishes its final rule which is anticipated in the fourth quarter of 2026.

As previously announced, a business update will occur via conference call on August 7, 2026 at 8:30 a.m. EST. Materials for the conference call are included on the Company’s website at http://www.sanuwave.com/investors.

Telephone access to the call will be available by dialing the following numbers:

Toll Free:1-800-274-8461

Toll/International: 1-203-518-9814

Conference ID: SANUWAVE

OR use the link for instant telephone access to the event.

https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5

A replay will be made available through August 21, 2026:

Toll-Free: 1-844-512-2921

Toll/International: 1-412-317-6671

Replay Access ID: 11162356

[1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information.

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Non-GAAP Financial Measures

This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP.

The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss), as a measure of financial performance or any other performance measure derived in accordance with U.S. GAAP, and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to U.S. GAAP measures, allows them to see the Company’s results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other U.S. GAAP measures.

EBITDA, Adjusted EBITDA, Adjusted Gross Margin Percentage and Adjusted Operating Income have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under U.S. GAAP. For example, some of these limitations are that EBITDA and Adjusted EBITDA:

•Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments.

•Do not reflect all changes in our working capital needs.

•Do not reflect interest expense, or the amount necessary to service our outstanding debt.

As presented in the U.S. GAAP to Non-GAAP Reconciliations section below, the Company’s non-GAAP financial measures exclude the impact of certain charges that contribute to our net income (loss).

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: reductions, clawbacks, or recoupments of CMS reimbursement for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; risks associated with regulatory oversight; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact: investors@sanuwave.com

SELECTED FINANCIAL DATA

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025

Three Months Ended June 30, Six Months Ended June 30,

(in thousands) 2026 2025 2026 2025

Revenue $ 9,739 $ 10,054 $ 19,358 $ 19,387

Cost of Revenues 2,315 2,206 4,502 4,164

Gross Margin 7,424 7,848 14,856 15,223

Gross Margin % 76.2 % 78.1 % 76.7 % 78.5 %

Total operating expenses 7,704 6,410 16,260 13,184

Operating (Loss) Income $ (280) $ 1,438 $ (1,404) $ 2,039

Total other expense (396) (887) (711) (7,606)

Net (Loss) Income $ (682) $ 551 $ (2,121) $ (5,567)

NON-GAAP ADJUSTED EBITDA

Three Months Ended June 30, Six Months Ended June 30,

(in thousands) 2026 2025 2026 2025

Net (Loss) Income $ (682) $ 551 $ (2,121) $ (5,567)

Non-GAAP Adjustments:

Interest expense 518 1,939 1,064 3,848

Depreciation and amortization 1

313 226 607 493

EBITDA 149 2,716 (450) (1,226)

Non-GAAP Adjustments for Adjusted EBITDA:

Change in fair value of derivative liabilities - (990) - 3,911

Other non-cash or infrequent charges:

Stock-based compensation 1,572 1,132 3,143 2,116

State & local sales tax 2

(532) 329 (194) 705

Sale of excess inventory - - (220) -

Adjusted EBITDA $ 1,189 $ 3,188 $ 2,279 $ 5,506

1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation. This change had no effect on previously reported GAAP results.

2 The charges represent a non-recurring state and local sales tax expense related to the restatement of prior period financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, 2026 December 31, 2025

ASSETS

Current Assets:

Cash and cash equivalents $ 9,376 $ 11,959

Accounts receivable, net of allowance of $1,617 and $1,265, respectively

5,801 5,422

Inventory 7,070 5,934

Prepaid expenses and other current assets 954 1,312

Total Current Assets 23,201 24,627

Non-Current Assets:

Property and equipment, net 2,255 1,972

Right of use assets, net 953 390

Intangible assets, net 2,887 3,026

Goodwill 7,260 7,260

Secured revolving credit facility debt issuance costs, net 49 68

Total Non-current Assets 13,404 12,716

Total Assets $ 36,605 $ 37,343

LIABILITIES

Current Liabilities:

Current portion of secured term loan, net of debt issuance costs $ 5,599 $ 5,638

Accounts payable 3,308 3,251

Accrued expenses 8,605 8,382

Current portion of operating lease liabilities 5 157

Current portion of contract liabilities 632 388

Accrued interest 17 24

Other 7 7

Total Current Liabilities 18,173 17,847

Non-current Liabilities:

Secured term loan, net of current portion and debt issuance costs 12,922 15,667

Secured revolving credit facility 655 655

Operating lease liabilities, less current portion 1,525 854

Contract liabilities, less current portion 543 701

Total Non-current Liabilities 15,645 17,877

Total Liabilities $ 33,818 $ 35,724

STOCKHOLDERS’ EQUITY

Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D designated, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025

$ - $ -

Common stock, par value $0.001, 2,500,000,000 shares authorized; 8,602,309 and 8,588,876 issued and outstanding at June 30, 2026 and December 31, 2025, respectively

9 9

Additional paid-in capital 247,574 244,285

Accumulated deficit (244,806) (242,685)

Accumulated other comprehensive income 10 10

Total Stockholders’ Equity 2,787 1,619

Total Liabilities and Stockholders’ Equity $ 36,605 $ 37,343

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

Three Months Ended June 30, Six Months Ended June 30,

2026 2025

(As Restated) 2026 2025

(As Restated)

Revenue $ 9,739 $ 10,054 $ 19,358 $ 19,387

Cost of Revenues 2,315 2,206 4,502 4,164

Gross Margin 7,424 7,848 14,856 15,223

Operating Expenses:

General and administrative 4,902 4,368 10,152 9,211

Selling and marketing 1,923 1,674 4,322 3,205

Research and development 628 194 1,289 402

Depreciation and amortization 251 174 497 366

Total Operating Expenses 7,704 6,410 16,260 13,184

Operating (Loss) Income (280) 1,438 (1,404) 2,039

Other (Expense) Income:

Interest expense (518) (1,939) (1,064) (3,848)

Change in fair value of derivative liabilities - 990 - (3,911)

Other expense (77) (27) (137) (28)

Other income

199 89 490 181

Total Other Expense, net (396) (887) (711) (7,606)

Net (Loss) Income Before Income Taxes (676) 551 (2,115) (5,567)

Income tax expense 6 - 6 -

Net (Loss) Income $ (682) $ 551 $ (2,121) $ (5,567)

(Loss) Earnings per Share:

Basic $ (0.08) $ 0.06 $ (0.25) $ (0.65)

Diluted $ (0.08) $ (0.04) $ (0.25) $ (0.65)

Weighted average shares outstanding

Basic 8,601,198 8,561,737 8,596,148 8,554,706

Diluted 8,601,198 9,167,846 8,596,148 8,554,706

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(In thousands, except share data)

Three Months Ended June 30, 2026

Common Stock

Number of

Issued and

Outstanding Par Value Additional Paid-

in Capital Accumulated

Deficit Accumulated

Other

Comprehensive

Income Total

Balances as of March 31, 2026 8,594,209 $ 9 $ 245,943 $ (244,124) $ 10 $ 1,838

Stock-based compensation - - 1,403 - - 1,403

Stock options exercised 4,100 - 58 - - 58

Shares issued for services rendered 4,000 - 67 - - 67

Shares granted in lieu of board of director fees - - 102 - - 102

Net loss

- - - (682) - (682)

Balances as of June 30, 2026 8,602,309 $ 9 $ 247,574 $ (244,806) $ 10 $ 2,787

Three Months Ended June 30, 2025

Common Stock

Number of

Issued and

Outstanding Par Value Additional Paid-

in Capital Accumulated

Deficit Accumulated

Other

Comprehensive

Income Total

Balances as of March 31, 2025 (As Restated) 8,548,473 $ 9 $ 239,786 $ (260,617) $ 10 $ (20,812)

Stock-based compensation - - 1,132 - - 1,132

Stock options exercised 17,008 - 253 - - 253

Shares granted in lieu of board of director fees 2,524 - 77 - - 77

Net income (As Restated)

- - - 551 - 551

Balances as of June 30, 2025 (As Restated) 8,568,005 $ 9 $ 241,248 $ (260,066) $ 10 $ (18,799)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(In thousands, except share data)

Six Months Ended June 30, 2026

Common Stock

Number of

Issued and

Outstanding Par Value Additional Paid-

in Capital Accumulated

Deficit Accumulated

Other

Comprehensive

Income Total

Balances as of December 31, 2025 8,588,876 $ 9 $ 244,285 $ (242,685) $ 10 $ 1,619

Stock-based compensation - 2,842 - - 2,842

Stock options exercised 5,433 - 77 - - 77

Shares issued for services rendered 8,000 - 164 - - 164

Shares granted in lieu of board of director fees - - 205 - - 205

Net loss - - - (2,121) - (2,121)

Balances as of June 30, 2026 8,602,309 $ 9 $ 247,574 $ (244,806) $ 10 $ 2,787

Six Months Ended June 30, 2025

Common Stock

Number of

Issued and

Outstanding Par Value Additional Paid-

in Capital Accumulated

Deficit Accumulated

Other

Comprehensive

Income Total

Balance as of December 31, 2024 (As Restated) 8,543,686 $ 9 $ 238,685 $ (254,499) $ 10 $ (15,795)

Stock-based compensation 4,787 - 2,233 - - 2,233

Stock options exercised 17,008 - 253 - - 253

Shares granted in lieu of board of director fees 2,524 - 77 - - 77

Net loss (As Restated) - - - (5,567) - (5,567)

Balances as of June 30, 2025 (As Restated) 8,568,005 $ 9 $ 241,248 $ (260,066) $ 10 $ (18,799)

CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30,

(in thousands)

2026 2025

(As Restated)

Operating Activities:

Net loss $ (2,121) $ (5,567)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities

Stock-based compensation 3,143 2,106

Depreciation and amortization 607 388

Amortization of right-of-use leases 56 185

Provision for credit losses 379 131

Change in fair value of derivative liabilities - 3,911

Amortization of debt issuance and debt discounts 111 1,062

Write-off of inventory 69 -

Loss on disposal of assets 18 -

Proceeds from tenant improvement funds - 429

Changes in operating assets and liabilities

Accounts receivable (757) (650)

Inventory (1,205) (1,762)

Prepaid expenses and other assets 385 (1,231)

Accounts payable (133) 274

Accrued expenses and contract liabilities 370 200

Operating leases (100) -

Net Cash Provided by (Used in) Operating Activities 822 (524)

Investing Activities

Purchase of property and equipment

(357) (1,321)

Deposits on property and equipment (35) -

Investment in software development (213) -

Net Cash Used in Investing Activities (606) (1,321)

Financing Activities

Proceeds from exercises of stock options 77 253

Repayment of principal secured term loan (2,875) -

Payments of principal on finance leases - (149)

Net Cash (Used in) Provided by Financing Activities (2,798) 104

Net Change in Cash During Period (2,583) (1,741)

Cash at Beginning of Period

11,959 10,237

Cash at End of Period

$ 9,376 $ 8,496

Supplemental Information:

Cash paid for interest $ 828 $ 2,255

Cash paid for income taxes $ 51 $ -

Non-cash Investing and Financing Activities:

Right-of-use assets obtained in exchange for lease liabilities 619 430

Stock options granted in lieu of cash bonus 69 117

Purchases of property and equipment in accounts payable 191 -

Capitalize interest into senior secured debt - 407

RSUs granted in exchange for services - 10

GRAPHIC

Filename: logoa.jpg · Sequence: 6

Binary file (11858 bytes)

Download logoa.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

SANUWAVE Health, Inc.

Entity Incorporation, State or Country Code

Entity File Number

000-42552

Entity Tax Identification Number

20-1176000

Entity Address, Address Line One

9600 W. 76th Street, Suite 118,

Entity Address, City or Town

Eden Prairie,

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

(952)

Local Phone Number

656-1029

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0001417663

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration